Involvement of Mast Cells in Systemic Sclerosis
Overview
Authors
Affiliations
Systemic sclerosis is characterized by tissue fibrosis, obliterative microangiopathy and immune abnormalities. The etiology of SSc is largely unknown and is known to be resistant to existing corticosteroid and immunosuppressive drugs. Therefore, establishment of a treatment strategy especially for SSc patients with organ involvement is strongly desired. Mast cells are widely recognized as effector cells in allergic disorders and other IgE-mediated immune responses. However, recently, mast cells have become known to play a role in bridging innate immunity and adaptive immunity. Additionally, there is growing evidence of mast cell to be involved in pathogenesis of rheumatoid arthritis, and is expected as a novel therapeutic target. We describe here the role of mast cell in SSc pathology and suggest as a novel therapeutic target.
Gong P, Ding Y, Sun R, Jiang Z, Li W, Su X Cell Death Discov. 2022; 8(1):466.
PMID: 36435837 PMC: 9701228. DOI: 10.1038/s41420-022-01264-2.
Interleukin-9 over-expression and T helper 9 polarization in systemic sclerosis patients.
Guggino G, Lo Pizzo M, Di Liberto D, Rizzo A, Cipriani P, Ruscitti P Clin Exp Immunol. 2017; 190(2):208-216.
PMID: 28681919 PMC: 5629425. DOI: 10.1111/cei.13009.
Mastocytosis and systemic sclerosis: a clinical association.
Bagnato G, Neal Roberts W, Sciortino D, Sangari D, Cirmi S, Ravenell R Clin Mol Allergy. 2016; 14:13.
PMID: 27752240 PMC: 5059924. DOI: 10.1186/s12948-016-0050-3.
Ningyan G, Xu Y, Hongfei S, Jingjing C, Min C PLoS One. 2015; 10(3):e0122482.
PMID: 25826375 PMC: 4380314. DOI: 10.1371/journal.pone.0122482.
Fibrosis--a lethal component of systemic sclerosis.
Ho Y, Lagares D, Tager A, Kapoor M Nat Rev Rheumatol. 2014; 10(7):390-402.
PMID: 24752182 DOI: 10.1038/nrrheum.2014.53.